Holen Sie sich die Stockscreener-App
72.13
1.93%
-1.42
Handel nachbörslich:
72.07
-0.06
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$73.55
Offen:
$73.25
24-Stunden-Volumen:
3.21M
Relative Volume:
0.90
Marktkapitalisierung:
$28.90B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$576.20M
KGV:
50.44
EPS:
1.43
Netto-Cashflow:
$630.70M
1W Leistung:
-1.70%
1M Leistung:
-19.78%
6M Leistung:
+6.81%
1J Leistung:
-48.45%
1-Tages-Spanne:
$71.47
$73.40
1-Wochen-Bereich:
$71.47
$76.27
52-Wochen-Spanne:
$62.34
$141.99
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.13 | 28.90B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
126.61 | 219.58B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.34 | 151.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.77 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.23 | 115.57B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.09 | 41.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Dexcom’s FDA warning letter reveals unauthorized changes to sensors - MedTech Dive
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor - Yahoo Finance
DexCom, Inc. (DXCM) Announces Change in Independent Auditors - GuruFocus.com
DexCom appoints Deloitte as new auditor, replacing EY - Investing.com India
DexCom Names Jon Coleman as Chief Commercial Officer - Marketscreener.com
DexCom names Jon Coleman as new chief commercial officer - Investing.com India
FDA warns Dexcom over continuous glucose monitor testing - Modern Healthcare
Dexcom Appoints Jon Coleman As Chief Commercial Officer - Marketscreener.com
Dexcom Appoints Jon Coleman as Chief Commercial Officer - Bluefield Daily Telegraph
Healthcare Pioneer Dexcom Taps 30-Year Industry Leader to Drive Global Growth - StockTitan
Citi maintains Buy rating on DexCom stock with $104 target By Investing.com - Investing.com UK
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom - 01Net
A unique opportunity to say thank you - The Persistent Pursuit
DexCom (DXCM): 3 Reasons We Love This Stock - Yahoo Finance
DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong: Analyst - MSN
Is DexCom Gaining or Losing Market Support? - Benzinga
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - MedTech Dive
Dexcom director Heller sells $24,756 in stock By Investing.com - Investing.com Canada
Dexcom director Heller sells $24,756 in stock - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom Welcome Renée Galá to its Board of Directors - MPO-mag
Buy, Sell, Or Hold DXCM Stock At $70? - Forbes
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care - 01Net
Dexcom's Game-Changing CGM Achieves Industry-Best 8.0% MARD, Doctors Choose Tech Over Drugs - StockTitan
DexCom, Inc. (DXCM): Among the Best Diabetes Stocks to Buy According to Billionaires - Yahoo Finance
Insulet's Game-Changing Automated Insulin System Expands Global Reach to Australia, Belgium, Canada - StockTitan
74,737 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Proficio Capital Partners LLC - Defense World
Dexcom’s chief legal officer sells $914,941 in stock By Investing.com - Investing.com Australia
Dexcom CFO sells shares for over $844,000 By Investing.com - Investing.com Australia
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management - Business Wire
10 Best Diabetes Stocks To Buy According to Billionaires - Insider Monkey
Dexcom EVP Jacob Steven Leach sells stock for $990,670 By Investing.com - Investing.com Australia
Dexcom’s chief legal officer sells $914,941 in stock - Investing.com
Dexcom’s EVP Sadie Stern sells $786,567 in stock - Investing.com
Looking At DexCom's Recent Unusual Options Activity - Benzinga
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter - Yahoo Finance
William Blair Forecasts DexCom’s Q1 Earnings (NASDAQ:DXCM) - Defense World
Is DexCom Stock Underperforming the Dow? - MSN
Non-Invasive Blood Glucose Monitoring Devices Market Is Booming Worldwide 2025-2032:Dexcom, Inc,Opticology - EIN News
Is DexCom Stock Underperforming The Dow? - Barchart
Head to Head Contrast: DexCom (NASDAQ:DXCM) vs. Biotricity (NASDAQ:BTCY) - Defense World
Dexcom’s CFO Sylvain sells shares worth $516,830 By Investing.com - Investing.com South Africa
Dexcom’s CFO Sylvain sells shares worth $516,830 - Investing.com India
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenue - Yahoo Finance
DexCom Options Trading: A Deep Dive into Market Sentiment - Benzinga
SBI Securities Co. Ltd. Makes New Investment in DexCom, Inc. (NASDAQ:DXCM) - Defense World
DexCom continues decline following FDA warning letter - MSN
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom receives warning letter based on FDA inspections of 2 plants - MedTech Dive
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter - Investopedia
DexCom, Inc. Appoints Renée Galá as A Director -March 10, 2025 at 08:31 am EDT - Marketscreener.com
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):